Initial therapy for acute myeloid leukemia in older patients: principles of care

References

• Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood. 2006;107:3481–3485.
   PubMed Web of Science ®Google Scholar
• Klepin HD, Geiger AM, Tooze JA, et al. The feasibility of inpatient geriatric assessment for older adults receiving induction chemotherapy for acute myelogenous leukemia. J Am Geriatr Soc. 2011;59:1837–1846.
   PubMed Web of Science ®Google Scholar
• Lindsley RC, Mar BG, Mazzola E, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015;125:1367–1376.
   PubMed Web of Science ®Google Scholar
• Thein MS, Ershler WB, Jemal A, et al. Outcome of older patients with acute myeloid leukemia: an analysis of SEER data over 3 decades. Cancer. 2013;119:2720–2727.
   PubMed Web of Science ®Google Scholar
• Upadhyay S, Dahal S, Khanal N, Bhatt VR, Silberstein PT. Chemotherapy in elderly patients with acute myeloid leukemia (AML): analysis of socioeconomic factors using national cancer data base (NCDB). Blood. 2014;124:5267.
   Google Scholar
• Meyers JL, Yu YF, Davis KL. Medicare fee-for-service enrollees with acute myelogenous leukemia: an analysis of treatment patterns and patient survival. Blood. 2011;118:505.
   Web of Science ®Google Scholar
• Alibhai SM, Leach M, Minden MD, et al. Outcomes and quality of care in acute myeloid leukemia over 40 years. Cancer. 2009;115:2903–2911.
   PubMed Web of Science ®Google Scholar
• Bhatt VR, Chen B, Lee S. Determinants of receipt of hematopoietic cell transplantation (HCT) in younger patients with acute myeloid leukemia (AML). ASCO 2016 Annual Meeting; 2016 Jun 3–7; Chicago (IL).
   Google Scholar
• Bhatt VR, Chen B, Lee S. Hematopoietic cell transplantation (HCT) in older patients with acute myeloid leukemia (AML). ASCO 2016 Annual Meeting; 2016 Jun 3–7; Chicago (IL).
   Google Scholar
• Meyers J, Yu Y, Kaye JA, et al. Medicare fee-for-service enrollees with primary acute myeloid leukemia: an analysis of treatment patterns, survival, and healthcare resource utilization and costs. Appl Health Econ Health Policy. 2013;11:275–286.
   PubMedGoogle Scholar
• Oran B, Weisdorf DJ. Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica. 2012;97:1916–1924.
   PubMed Web of Science ®Google Scholar
• Freireich EJ, Wiernik PH, Steensma DP. The leukemias: a half-century of discovery. J Clin Oncol. 2014;32:3463–3469.
   PubMed Web of Science ®Google Scholar
• Fried TR, Bradley EH, Towle VR, et al. Understanding the treatment preferences of seriously ill patients. N Engl J Med. 2002;346:1061–1066.
   PubMed Web of Science ®Google Scholar
• Azoulay E, Mokart D, Pene F, et al. Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium – a groupe de recherche respiratoire en reanimation onco-hematologique study. J Clin Oncol. 2013;31:2810–2818.
   PubMed Web of Science ®Google Scholar
• Loggers ET, LeBlanc TW, El-Jawahri A, et al. Pretransplantation supportive and palliative care consultation for high-risk hematopoietic cell transplantation patients. Biol Blood Marrow Transplant. 2016;22:1299–1305.
   PubMed Web of Science ®Google Scholar
• Ganti AK, Lee SJ, Vose JM, et al. Outcomes after hematopoietic stem-cell transplantation for hematologic malignancies in patients with or without advance care planning. J Clin Oncol. 2007;25:5643–5648.
   PubMed Web of Science ®Google Scholar
• El-Jawahri A, Keenan T, Abel GA, et al. Potentially avoidable hospital admissions in older patients with acute myeloid leukaemia in the USA: a retrospective analysis. Lancet Haematol. 2016;3:e276–e283.
   PubMed Web of Science ®Google Scholar
• El-Jawahri AR, Abel GA, Steensma DP, et al. Health care utilization and end-of-life care for older patients with acute myeloid leukemia. Cancer. 2015;121:2840–2848.
   PubMed Web of Science ®Google Scholar
• Giri S, Shrestha R, Pathak R, et al. Racial differences in the overall survival of hairy cell leukemia in the united states: a population-based analysis of the surveillance, epidemiology, and end results database. Clin Lymphoma Myeloma Leuk. 2015;15:484–488.
   PubMed Web of Science ®Google Scholar
• Giri S, Shostrom V, Gundabolu K, et al. Overall survival (OS) of acute myeloid leukemia (AML) treated at academic center (AC) versus non-academic center (NAC). 57th ASH Annual Meeting; 2015 Dec 7; Orlando (FL).
   Google Scholar
• Ferro RA, Shostrom V, Vose JV, et al. Overall survival (OS) of acute lymphoblastic leukemia (ALL) is better when initial therapy is administered in academic hospitals (AH) versus non-academic hospitals (NAH): a retrospective analysis of the national cancer data base (NCDB). 57th ASH Annual Meeting; 2015 Dec 6; Orlando (FL).
   Google Scholar
• Aizer AA, Chen M-H, McCarthy EP, et al. Marital status and survival in patients with cancer. J Clin Oncol. 2013;31:3869–3876.
   PubMed Web of Science ®Google Scholar
• Muffly LS, Kocherginsky M, Stock W, et al. Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. Haematologica. 2014;99:1373–1379.
   PubMed Web of Science ®Google Scholar
• Tawfik B, Pardee TS, Isom S, et al. Comorbidity, age, and mortality among adults treated intensively for acute myeloid leukemia (AML). J Geriatr Oncol. 2016;7:24–31.
   PubMed Web of Science ®Google Scholar
• Klepin HD, Geiger AM, Tooze JA, et al. Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. Blood. 2013;121:4287–4294.
   PubMed Web of Science ®Google Scholar
• Dohner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373:1136–1152.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100:4325–4336.
   PubMed Web of Science ®Google Scholar
• Gardin C, Chevret S, Pautas C, et al. Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older. J Clin Oncol. 2013;31:321–327.
   PubMed Web of Science ®Google Scholar
• Lowenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009;361:1235–1248.
   PubMed Web of Science ®Google Scholar
• Bhatt VR. Leukemic transformation in essential thrombocythemia. Future Oncol. 2014;10:2593–2602.
   PubMed Web of Science ®Google Scholar
• Bhatt VR, Giri S, Verma V, et al. Secondary acute myeloid leukemia in survivors of Hodgkin lymphoma. Future Oncol. 2016;12:1565–1575.
   PubMed Web of Science ®Google Scholar
• Bhatt VR, Steensma DP. Hematopoietic cell transplantation for myelodysplastic syndromes. J Oncol Pract. 2016;12:786–792.
   PubMed Web of Science ®Google Scholar
• Pidala J, Kim J, Schell M, et al. Race/ethnicity affects the probability of finding an HLA-A, -B, -C and -DRB1 allele-matched unrelated donor and likelihood of subsequent transplant utilization. Bone Marrow Transplant. 2013;48:346–350.
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Ravandi F, Liu-Dumlao T, et al. Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. Blood. 2012;120:4840–4845.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Ravandi F, O'Brien S, et al. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood. 2010;116:4422–4429.
   PubMed Web of Science ®Google Scholar
• Wheatley K, Brookes CL, Howman AJ, et al. Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials. Br J Haematol. 2009;145:598–605.
   PubMed Web of Science ®Google Scholar
• Krug U, Rollig C, Koschmieder A, et al. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. Lancet. 2010;376:2000–2008.
   PubMed Web of Science ®Google Scholar
• Walter RB, Othus M, Borthakur G, et al. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol. 2011;29:4417–4423.
   PubMed Web of Science ®Google Scholar
• Mohile SG, Bylow K, Dale W, et al. A pilot study of the vulnerable elders survey-13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablation. Cancer. 2007;109:802–810.
   PubMed Web of Science ®Google Scholar
• Soubeyran P, Bellera C, Goyard J, et al. Validation of the G8 screening tool in geriatric oncology: the ONCODAGE project. ASCO Meeting Abstracts. 2011;29(15_suppl):9001.
   Google Scholar
• Deschler B, Ihorst G, Platzbecker U, et al. Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome. Haematologica. 2013;98:208–216.
   PubMed Web of Science ®Google Scholar
• Wedding U, Rohrig B, Klippstein A, et al. Impairment in functional status and survival in patients with acute myeloid leukaemia. J Cancer Res Clin Oncol. 2006;132:665–671.
   PubMed Web of Science ®Google Scholar
• Naeim A, Aapro M, Subbarao R, et al. Supportive care considerations for older adults with cancer. J Clin Oncol. 2014;32:2627–2634.
   PubMed Web of Science ®Google Scholar
• Klepin HD, Tooze JA, Pardee TS, et al. Effect of intensive chemotherapy on physical, cognitive, and emotional health of older adults with acute myeloid leukemia. J Am Geriatr Soc. 2016;64:1988–1995.
   PubMed Web of Science ®Google Scholar
• Klepin HD, Rao AV, Pardee TS. Acute myeloid leukemia and myelodysplastic syndromes in older adults. J Clin Oncol. 2014;32:2541–2552.
   PubMed Web of Science ®Google Scholar
• Hurria A, Dotan E, Baumgartner J, et al. NCCN Clinical Practice Guidelines in Oncology. Older Adult Oncology version 2. 2016 – [cited 2016 Sep 20]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/senior.pdf
   Google Scholar
• Gajra A, Loh KP, Hurria A, et al. Comprehensive geriatric assessment-guided therapy does improve outcomes of older patients with advanced lung cancer. J Clin Oncol. 2016;34:4047–4048.
   PubMed Web of Science ®Google Scholar
• Takahashi K, Kantarjian H, Garcia-Manero G, et al. Clofarabine plus low-dose cytarabine is as effective as and less toxic than intensive chemotherapy in elderly AML patients. Clin Lymphoma Myeloma Leuk. 2016;16:163–168, e161–162.
   PubMed Web of Science ®Google Scholar
• Foran JM, Sun Z, Claxton DF, et al. North American leukemia, intergroup phase III randomized trial of single agent clofarabine as induction and post-remission therapy, and decitabine as maintenance therapy in newly-diagnosed acute myeloid leukemia in older adults (age ≥60 years): a trial of the ECOG-ACRIN Cancer Research Group (E2906). Blood. 2015;126:217.
   Web of Science ®Google Scholar
• Lubbert M, Ruter BH, Claus R, et al. A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy. Haematologica. 2012;97:393–401.
   PubMed Web of Science ®Google Scholar
• Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015;126:291–299.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellström-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010;28:562–569.
   PubMed Web of Science ®Google Scholar
• Pautas C, Merabet F, Thomas X, et al. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study. J Clin Oncol. 2010;28:808–814.
   PubMed Web of Science ®Google Scholar
• Castaigne S, Pautas C, Terre C, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012;379:1508–1516.
   PubMed Web of Science ®Google Scholar
• Amadori S, Suciu S, Selleslag D, et al. Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of the randomized phase III EORTC-GIMEMA AML-19 Trial. J Clin Oncol. 2016;34:972–979.
   PubMed Web of Science ®Google Scholar
• Burnett AK, Russell NH, Hills RK, et al. A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia. Leukemia. 2017;31:310–317.
   PubMed Web of Science ®Google Scholar
• Burnett AK, Russell NH, Hills RK, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol. 2012;30:3924–3931.
   PubMed Web of Science ®Google Scholar
• Lancet JE, Cortes JE, Hogge DE, et al. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. Blood. 2014;123:3239–3246.
   PubMed Web of Science ®Google Scholar
• Lancet J, Uy G, Cortes J, et al. CPX-351 treatment of previously untreated older AML patients with high risk AML markedly increases the response rate over 7 + 3 in patients with FLT3 mutations. Abstract # S502 presented at the 2016 European Hematology Association Annual Meeting, Copenhagen, Denmark; 2016 Jun 9–12.
   Google Scholar
• Pigneux A, Béné MC, Guardiola P, et al. Addition of androgens improves survival in elderly patients with acute myeloid leukemia: a GOELAMS study. J Clin Oncol. 2017;35:387–393.
   Web of Science ®Google Scholar
• Versluis J, Hazenberg CL, Passweg JR, et al. Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis. Lancet Haematol. 2015;2:e427–e436.
   PubMed Web of Science ®Google Scholar
• Döhner H, Lübbert M, Fiedler W, et al. Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy. Blood. 2014;124:1426–1433.
   PubMed Web of Science ®Google Scholar
• Döhner H, Symeonidis A, Sanz MA, et al. Phase III randomized trial of volasertib plus low-dose cytarabine (LDAC) versus placebo plus LDAC in patients aged ≥65 years with previously untreated AML, ineligible for intensive therapy. Abstract # S501 presented at the 2016 European Hematology Association Annual Meeting, Copenhagen, Denmark; 2016 Jun 9–12.
   Google Scholar
• Jurcic JG. Highlights in hematologic malignancy treatments: leukemia, myelodysplastic syndromes, and allotransplant-new drugs on the horizon for acute myeloid leukemia. JAMA Oncol. 2017;3:299–300.
   PubMed Web of Science ®Google Scholar
• Stein AS, Walter RB, Erba HP, et al. A phase 1 trial of SGN-CD33A as monotherapy in patients with CD33-positive acute myeloid leukemia (AML). Blood. 2015;126:324–324.
   Google Scholar
• Stone RM, Mandrekar S, Sanford BL, et al. The multi-kinase inhibitor midostaurin (M) prolongs survival compared with placebo (P) in combination with daunorubicin (D)/cytarabine (C) induction (ind), high-dose C consolidation (consol), and as maintenance (maint) therapy in newly diagnosed acute myeloid leukemia (AML) patients (pts) age 18–60 with FLT3 mutations (muts): an international prospective randomized (rand) P-controlled double-blind trial (CALGB 10603/RATIFY [Alliance]). Blood. 2015;126:6.
   PubMed Web of Science ®Google Scholar
• Cooper BW, Kindwall-Keller TL, Craig MD, et al. A phase i study of midostaurin and azacitidine in relapsed and elderly AML patients. Clin Lymphoma Myeloma Leuk. 2015;15:428–432.e422.
   PubMed Web of Science ®Google Scholar
• Burnett AK, Milligan D, Prentice AG, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer. 2007;109:1114–1124.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30:2670–2677.
   PubMed Web of Science ®Google Scholar
• Blum W, Garzon R, Klisovic RB, et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci USA. 2010;107:7473–7478.
   PubMed Web of Science ®Google Scholar
• Blum W, Klisovic RB, Hackanson B, et al. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol. 2007;25:3884–3891.
   PubMed Web of Science ®Google Scholar
• Ritchie EK, Feldman EJ, Christos PJ, et al. Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia. Leuk Lymphoma. 2013;54:2003–2007.
   PubMed Web of Science ®Google Scholar
• Welch JS, Petti AA, Miller CA, et al. TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes. N Engl J Med. 2016;375:2023–2036.
   PubMed Web of Science ®Google Scholar
• Stirewalt DL, Kopecky KJ, Meshinchi S, et al. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood. 2001;97:3589–3595.
   PubMed Web of Science ®Google Scholar
• Kropf P, Jabbour E, Yee K, et al. Late responses and overall survival (OS) from long term follow up of a randomized phase II study of SGI-110 (guadecitabine) 5-day regimen in elderly AML who are not eligible for intensive chemotherapy [abstract]. 20th Congress of the European Hematology Association; 2015 Jun 11–14; Vienna, Austria. Abstract P571.
   Google Scholar
• Burnett AK, Russell NH, Hunter AE, et al. Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival. Blood. 2013;122:1384–1394.
   PubMed Web of Science ®Google Scholar
• Faderl S, Ravandi F, Huang X, et al. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood. 2008;112:1638–1645.
   PubMed Web of Science ®Google Scholar
• Kadia TM, Faderl S, Ravandi F, et al. Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. Cancer. 2015;121:2375–2382.
   PubMed Web of Science ®Google Scholar
• Burnett AK, Hills RK, Hunter AE, et al. The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison. Leukemia. 2013;27:75–81.
   PubMed Web of Science ®Google Scholar
• Nand S, Othus M, Godwin JE, et al. A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia. Blood. 2013;122:3432–3439.
   PubMed Web of Science ®Google Scholar
• Fathi A, Erba H, Lancet J, et al. SGN-CD33A in combination with hypomethylating agents: A novel, well-tolerated regimen with high remission rate in older patients with AML. Abstract # S503 presented at the 2016 European Hematology Association Annual Meeting, Copenhagen, Denmark; 2016 Jun 9–12.
   Google Scholar
• Lin TL, Strickland SA, Fiedler W, et al. Phase Ib/2 study of venetoclax with low-dose cytarabine in treatment-naive patients age ≥65 with acute myelogenous leukemia. J Clin Oncol. 2016;34:(suppl; abstr 7007).
   Web of Science ®Google Scholar
• Daver N, Kantarjian H, Garcia-Manero G, et al. Phase I/II study of vosaroxin and decitabine in newly diagosed older patients (pts) with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Abstract # S505 presented at the 2016 European Hematology Association Annual Meeting, Copenhagen, Denmark; 2016 Jun 9–12.
   Google Scholar
• Garcia-Manero G, Atallah E, Khaled SK, et al. Final results from a phase 2 study of pracinostat in combination with azacitidine in elderly patients with acute myeloid leukemia (AML). Blood. 2015;126:453–453.
   Web of Science ®Google Scholar
• Jurcic JG, Ravandi F, Pagel JM, et al. Phase I trial of targeted alpha-particle immunotherapy with actinium-225 (225Ac)-lintuzumab (Anti-CD33) and low-dose cytarabine (LDAC) in older patients with untreated acute myeloid leukemia (AML). Blood. 2015;126:3794–3794.
   Web of Science ®Google Scholar
• Goyal G, Gundabolu K, Vallabhajosyula S, et al. Reduced-intensity conditioning allogeneic hematopoietic-cell transplantation for older patients with acute myeloid leukemia. Ther Adv Hematol. 2016;7:131–141.
   PubMed Web of Science ®Google Scholar
• Bhatt VR. Allogeneic stem cell transplantation for non-Hodgkin lymphoma. Curr Hematol Malig Rep. 2016;11:196–207.
   PubMed Web of Science ®Google Scholar
• Bhatt VR, Armitage JO. Autologous and allogeneic hematopoietic stem cell transplantation in follicular lymphoma. Expert Opin Biol Ther. 2016;16:57–66.
   PubMed Web of Science ®Google Scholar
• Middeke JM, Herold S, Rucker-Braun E, et al. TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2016;172:914–922.
   PubMed Web of Science ®Google Scholar
• Mohr B, Schetelig J, Schafer-Eckart K, et al. Impact of allogeneic haematopoietic stem cell transplantation in patients with abnl(17p) acute myeloid leukaemia. Br J Haematol. 2013;161:237–244.
   PubMed Web of Science ®Google Scholar
• Bhatt VR, Loberiza FR Jr, Jing H, et al. Mortality patterns among recipients of autologous hematopoietic stem cell transplantation for lymphoma and myeloma in last three decades. Clin Lymphoma Myeloma Leuk. 2015. DOI:10.1016/j.clml.2015.02.024.
   Web of Science ®Google Scholar
• Giri S, Pathak R, Aryal MR, et al. Impact of hospital volume on outcomes of patients undergoing chemotherapy for acute myeloid leukemia: a matched cohort study. Blood. 2015;125:3359–3360.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–383.
   PubMedGoogle Scholar
• Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912–2919.
   PubMed Web of Science ®Google Scholar
• Giles FJ, Borthakur G, Ravandi F, et al. The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br J Haematol. 2007;136:624–627.
   PubMed Web of Science ®Google Scholar
• Sharma M, Loh KP, Nightingale G, et al. Polypharmacy and potentially inappropriate medication use in geriatric oncology. J Geriatr Oncol. 2016;7:346–353.
   PubMed Web of Science ®Google Scholar
• Rubenstein LZ, Harker JO, Salva A, et al. Screening for undernutrition in geriatric practice: developing the short-form mini-nutritional assessment (MNA-SF). J Gerontol A Biol Sci Med Sci. 2001;56:M366–M372.
   PubMed Web of Science ®Google Scholar
• Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–198.
   PubMed Web of Science ®Google Scholar
• Nasreddine ZS, Phillips NA, Bedirian V, et al. The montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53:695–699.
   PubMed Web of Science ®Google Scholar
• Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16:606–613.
   PubMed Web of Science ®Google Scholar
• Katz S, Ford AB, Moskowitz RW, et al. Studies of illness in the aged. The index of Adl: a standardized measure of biological and psychosocial function. JAMA. 1963;185:914–919.
   PubMed Web of Science ®Google Scholar
• Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9:179–186.
   PubMed Web of Science ®Google Scholar
• Podsiadlo D, Richardson S. The timed “Up & Go”: a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc. 1991;39:142–148.
   PubMed Web of Science ®Google Scholar
• Guralnik JM, Simonsick EM, Ferrucci L, et al. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol. 1994;49:M85–M94.
   PubMedGoogle Scholar
• Owusu C, Koroukian SM, Schluchter M, et al. Screening older cancer patients for a comprehensive geriatric assessment: a comparison of three instruments. J Geriatr Oncol. 2011;2:121–129.
   PubMed Web of Science ®Google Scholar
• DiNardo C, Pollyea D, Pratz K, et al. A Phase 1b study of venetoclax (ABT-199/GDC-0199) in combination with decitabine or azacitidine in treatment-naive patients with acute myelogenous leukemia who are ≥ to 65 years and not eligible for standard induction therapy. Blood. 2015;126:327–327.
   Web of Science ®Google Scholar